Nargenicin A1

CHF 155.00
In stock
BVT-0204-M0011 mgCHF 155.00
BVT-0204-M0055 mgCHF 505.00
More Information
Product Details
Synonyms CP-47,444; CS682
Product Type Chemical


MW 515.6
CAS 70695-02-2
Source/Host Chemicals Isolated from Actinomyces sp. Gö301.
Purity Chemicals ≥98% (HPLC)
Appearance Off-white powder.
Solubility Soluble in DMSO or methanol.
Identity Determined by 1H-NMR.
Declaration Manufactured by BioViotica.
Smiles [H][C@]12C=C[C@]3([H])C[C@H](OC)C(=O)O[C@]([H])([C@@H](C)O)[C@H](C)\C=C(C)\[C@]33O[C@H]1[C@H](OC(=O)C1=CC=CN1)[C@H](C)[C@@H](O)[C@]23[H]
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
After reconstitution protect from light at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Antibiotic against Gram-positive bacteria, particularly Staphylococcus and Clostridia.
  • More effective against multi-resistant strains (MRSA) than erythromycin and vancomycin.
  • Inhibits cell proliferation and induces HL-60 cell differentiation in combination with 1,25-Dihydroxyvitamin-D3 and ATRA.
  • Antioxidant.
Product References
  1. Structure of natural antibiotic CP-47,444: W.D. Celmer et al., J. Am. Chem. Soc. 102, 4203 (1980)
  2. Nargenicin biosynthesis: D.E. Cane et al., J. Am. Chem. Soc. 115, 527 (1993)
  3. The chemistry of the Nargenicin macrolides: J. Kallmerten, in Studies in natural products chemistry (Ed.: A.-U. Rahman, Elsevier) 17, 283 (1995)
  4. Production, isolation and biological activity of nargenicin from Nocardia sp. CS682: J.K. Sohng et al., Arch. Pharm. Res. 31, 1339 (2008)
  5. Quantitative analysis of nargenicin in Nocardia sp. CS682 culture by HPLC: S.S. Cho et al., Arch. Pharm. Res. 32, 335 (2009)
  6. Nargenicin attenuates lipopolysaccharide-induced responses in BV-2 cells: J.C. Yoo et al., Neuroreport 20, 1007 (2009)
  7. Nargenicin enhances 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced leukemia cell differentiation via PKCbetal/MAPK pathways: S.H. Kim et al., Biochemical Pharmacology 77, 1694 (2009)
  8. Enhanced production of nargenicin A1 and generation of novel glycosylated derivatives: D. Dhakal, et al.; Appl. Biochem. Biotechnol. 175, 2934 (2015)
  9. Biosynthesis and ether-bridge formation in nargenicin macrolides: S.J. Pidot, et al.; Angew. Chem. Int. Ed. 58, 3996 (2019)
  10. Protective effects of nargenicin A1 against tacrolimus-Induced oxidative stress in hirame natural embryo cells: C. Park, et al.; Int. J. Environ. Res. Public Health 16, 1044 (2019)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.